ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 143702" data-attributes="member: 13851"><p><span style="font-size: 26px"><strong>Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.</strong></span></p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Anushiravani%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30920975" target="_blank">Anushiravani A</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Haddadi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30920975" target="_blank">Haddadi N</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Pourfarmanbar%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30920975" target="_blank">Pourfarmanbar M</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Mohammadkarimi%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30920975" target="_blank">Mohammadkarimi V</a></p><p></p><p></p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/30920975" target="_blank">Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. - PubMed - NCBI</a></p><p></p><p></p><p></p><p></p><p></p><p><span style="font-size: 18px"><strong><span style="color: rgb(184, 49, 47)">Abstract</span></strong></span></p><p></p><p><strong>INTRODUCTION:</strong></p><p>Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation. Cardiovascular disease is the main cause of death in these patients. There is no Food and Drug Association-approved medication for NAFLD patients. We aimed to provide more robust evidence on the use of medications that are inexpensive and available, namely, metformin, silymarin, pioglitazone, and vitamin E, for treating NAFLD.</p><p></p><p><strong>MATERIALS AND METHODS:</strong></p><p>We conducted a randomized double-blinded, placebo-controlled trial on 150 consecutive patients with NAFLD who were assigned to five groups: <strong>lifestyle plus placebo,</strong> <strong><span style="color: rgb(184, 49, 47)">metformin 500 mg/day, silymarin 140 mg/day, pioglithasone 15 mg/day, and vitamin E 400 IU/day</span></strong>, all for 3 months. Anthropometric and biochemical variables were measured at baseline and 3 months later.</p><p></p><p><strong>RESULTS:</strong></p><p>The mean age of the patients was 47.0±9.1 (range: 18-65) years and the sex distribution was 73 (48.7%) women and 77 (51.3%) men. Patients in all groups showed a significant improvement in anthropometric parameters such as waist circumference and BMI. There was no statistically significant difference in alanine transaminase and aspartate transaminase in the control group after treatment (P=0.51, 0.18, respectively); however, both liver enzymes decreased significantly in the other groups.</p><p></p><p><strong>DISCUSSION AND CONCLUSION:</strong></p><p><strong>This randomized double-blinded placebo-controlled clinical trial suggested <span style="color: rgb(184, 49, 47)">a significant benefit of silymarin, pioglitazone, and vitamin E in improving liver aminotransferases in patients with NAFLD </span>after only 3 months, <span style="color: rgb(184, 49, 47)">without exerting any specific side effects.</span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 143702, member: 13851"] [SIZE=26px][B]Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.[/B][/SIZE] [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Anushiravani%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30920975']Anushiravani A[/URL], [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Haddadi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30920975']Haddadi N[/URL], [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Pourfarmanbar%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30920975']Pourfarmanbar M[/URL], [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Mohammadkarimi%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30920975']Mohammadkarimi V[/URL] [URL='https://www.ncbi.nlm.nih.gov/pubmed/30920975']Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. - PubMed - NCBI[/URL] [SIZE=18px][B][COLOR=rgb(184, 49, 47)]Abstract[/COLOR][/B][/SIZE] [B]INTRODUCTION:[/B] Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation. Cardiovascular disease is the main cause of death in these patients. There is no Food and Drug Association-approved medication for NAFLD patients. We aimed to provide more robust evidence on the use of medications that are inexpensive and available, namely, metformin, silymarin, pioglitazone, and vitamin E, for treating NAFLD. [B]MATERIALS AND METHODS:[/B] We conducted a randomized double-blinded, placebo-controlled trial on 150 consecutive patients with NAFLD who were assigned to five groups: [B]lifestyle plus placebo,[/B] [B][COLOR=rgb(184, 49, 47)]metformin 500 mg/day, silymarin 140 mg/day, pioglithasone 15 mg/day, and vitamin E 400 IU/day[/COLOR][/B], all for 3 months. Anthropometric and biochemical variables were measured at baseline and 3 months later. [B]RESULTS:[/B] The mean age of the patients was 47.0±9.1 (range: 18-65) years and the sex distribution was 73 (48.7%) women and 77 (51.3%) men. Patients in all groups showed a significant improvement in anthropometric parameters such as waist circumference and BMI. There was no statistically significant difference in alanine transaminase and aspartate transaminase in the control group after treatment (P=0.51, 0.18, respectively); however, both liver enzymes decreased significantly in the other groups. [B]DISCUSSION AND CONCLUSION: This randomized double-blinded placebo-controlled clinical trial suggested [COLOR=rgb(184, 49, 47)]a significant benefit of silymarin, pioglitazone, and vitamin E in improving liver aminotransferases in patients with NAFLD [/COLOR]after only 3 months, [COLOR=rgb(184, 49, 47)]without exerting any specific side effects.[/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top